Novo Nordisk announces the forthcoming acquisition of Cardior Pharmaceuticals for up to 1.025 billion euros, including an upfront payment and additional payments if certain development and commercial milestones are reached.

Cardior Pharmaceuticals is a leader in the discovery and development of RNA-targeted therapies to prevent, repair and reverse heart disease.

The agreement includes Cardior's lead compound 'CDR132L', currently in phase 2 clinical development for the treatment of heart failure.

This acquisition is an important step in Novo Nordisk's strategy to establish a presence in the field of cardiovascular disease.


Copyright (c) 2024 CercleFinance.com. All rights reserved.